Skip to main content

CD19x22 CAR T

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

  • RegistryNCT06559189
  • PhasePhase 1
  • StatusRecruiting
  • ConditionB-cell Acute Lymphoblastic Leukemia
  • SponsorUniversity of Colorado, Denver
How CD19x22 CAR T worksNCT065591891 min

What the film says

Read the transcript

Most children with B-cell leukemia are cured. For those who relapse twice, or relapse after transplant, or after CAR T therapy, the path narrows quickly.

The idea: a CAR T cell that recognizes two leukemia markers at once, built for children.

CD19 CAR T cells can fail when the leukemia stops displaying CD19. At Children's Hospital Colorado, a child's own T cells receive a receptor that binds both CD19 and CD22, so the leukemia has to lose both to escape. The cells are made in the university's own manufacturing facility, and given once after chemotherapy makes room.

Heavy and light disease are studied in parallel, from three months to age thirty, with careful dose escalation. Vanessa Fabrizio leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06559189

    Eligibility: ≥2 relapses, relapse after BMT, relapse after single-antigen CAR T, refractory; CD19 antigen loss as escape mechanism; Autologous CD19xCD22 CAR T made at the Gates Biomanufacturing Facility; Lymphodepletion then infusion (+2 more lines)

The drug

What is being tested.

The investigational product is an autologous, genetically modified CD19xCD22 CAR T cell product produced by the Gates Biomanufacturing Facility.

This is an open-label Phase I trial consisting of 2 cohorts to determine the safety and tolerability of CD19x22 CAR T in Pediatric Patients with R/R B-ALL.

This trial will include two parallel cohorts based on disease burden prior to lymphodepleting chemotherapy, Cohort 1: high disease burden cohort: defined as >=25% bone marrow lymphoblasts and/or non-CNS extramedullary disease, and Cohort 2: low disease burden cohort: defined as <25% bone marrow lymphoblasts and no non-CNS extramedullary disease. Dose escalation will proceed independently within each cohort using the Bayesian Optimal Interval (BOIN) design.

The study

How the trial runs.

This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Subjects must have a history of B precursor ALL with any of the following conditions:
  • Relapsed two or more times.
  • Relapsed at any time after allogeneic bone marrow transplant (BMT).
  • Relapse or refractory after single antigen targeting CAR T cell therapy.
  • i. 90 days must have elapsed post previous CAR infusion prior to apheresis. d. Refractory to standard therapy as determined by the treating physician. e. Patient and/or parents declining BMT options and would prefer CAR T Therapy.
  • CD19 and/or CD22 present on last relapsed/refractory disease evaluation.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.